According to filings with the U.S. Securities and Exchange Commission, Osanni Bio LLC has raised $190,000,000.00 in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Patient Square Capital, the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.

About Osanni Bio LLC
Osanni Bio is a development-stage therapeutics platform, headquartered in San Francisco, California. At the center of Osanni is its innovation engine, which is optimized for discovering new scientific insights, designing novel drug concepts, and efficiently advancing programs to a meaningful proof-of-concept. Once a program is sufficiently de-risked, it graduates into its ecosystem of affiliate companies, which are equipped with the dedicated focus, specialized talent and support necessary to scale. Osannis architecture marries the scientific depth and operational power of a centralized platform with the speed, agility and accountability of independent companies. The result: an opportunity to create and deliver more transformative medicines. Osanni is currently advancing programs in ophthalmology, cardiology and beyond.

To learn more, visit https://osanni.bio/
Linkedin: https://www.linkedin.com/company/osannibio/

Contact:
Michael Ackermann, Chief Executive Officer
https://www.linkedin.com/in/michaelackermann/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.